AbbVie (NYSE:ABBV) is one of the globe's top drugmakers and it's quickly become a staple in dividend investors' portfolios since separating from Abbott Labs in 2013.
Big drug companies, such as AbbVie, Johnson & Johnson (NYSE:JNJ), and Amgen (NASDAQ:AMGN), offer investors predictable, dividend-boosting revenue regardless of the economy's whims and whispers. But investors are correct to wonder if AbbVie's dividend can be sustained in light of billions in at-risk revenue tied to the future patent expiration on its top selling drug, Humira.
In the following slideshow you'll see whether I think AbbVie's dividend is safe and gain insight into how AbbVie matches up with industry peers.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.